In a recent filing, Farallon Capital Management revealed it had established a significant new position in Beam Therapeutics (BEAM), a biotechnology company focused on precision genetic medicines. The investment manager acquired 10.13 million shares, valued at $241.51 million as of the report date, giving the new stake a 1.38% weight in Farallon's portfolio. Farallon is known for its focus on the healthcare and biotech sectors.
Investors should note that this transaction was disclosed in a quarterly 13F filing, which reports holdings as of March 31, 2026, and was filed with the SEC on August 14, 2026. The trades, therefore, took place during the first quarter of the year. During that quarter, Beam announced progress on its therapy for alpha-1 antitrypsin deficiency (AATD), BEAM-302, and plans to pursue an accelerated approval pathway with the FDA.